The effects of strontium ranelate in Asian women with postmenopausal osteoporosis

J. S. Hwang, J. F. Chen, T. S. Yang, D. J. Wu, K. S. Tsai, C. Ho, Chih-Hsing Wu, S. L. Su, C. J. Wang, S. T. Tu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy and safety of strontium ranelate in the treatment of postmenopausal women with osteoporosis in Taiwan. In this 12-month multicenter, randomized, double-blind, placebo-controlled study, 125 women with osteoporosis were randomly given either strontium ranelate 2 g daily or placebo. Lumbar spine, femoral neck, and total-hip bone mineral density (BMD) and biochemical markers of bone turnover were measured; adverse events and tolerability were recorded and assessed. Subjects treated with strontium ranelate showed significant increases in BMD of 5.9% at the lumbar spine, 2.6% at the femoral neck, and 2.7% at the total hip, while the placebo group exhibited no significant change at 12 months. Serum level of a formation marker (bone-specific alkaline phosphatase) was also significantly increased at 6 and 12 months. Thus, although the sample size and the treatment duration of this study could not show its effect of reducing osteoprotic fractures, strontium ranelate showed bone protection effects by increasing BMD and concentrations of a bone formation marker. Safety assessment revealed adverse events were mild and not significantly different from placebo.

Original languageEnglish
Pages (from-to)308-314
Number of pages7
JournalCalcified Tissue International
Volume83
Issue number5
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

strontium ranelate
Postmenopausal Osteoporosis
Placebos
Bone Density
Femur Neck
Osteogenesis
Osteoporosis
Spine
Pelvic Bones
Safety
Bone Remodeling
Taiwan
Sample Size
Alkaline Phosphatase
Hip
Biomarkers
Bone and Bones
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Hwang, J. S., Chen, J. F., Yang, T. S., Wu, D. J., Tsai, K. S., Ho, C., ... Tu, S. T. (2008). The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Calcified Tissue International, 83(5), 308-314. https://doi.org/10.1007/s00223-008-9180-z
Hwang, J. S. ; Chen, J. F. ; Yang, T. S. ; Wu, D. J. ; Tsai, K. S. ; Ho, C. ; Wu, Chih-Hsing ; Su, S. L. ; Wang, C. J. ; Tu, S. T. / The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. In: Calcified Tissue International. 2008 ; Vol. 83, No. 5. pp. 308-314.
@article{00f0cc94a0a449b681ae6aa0c6767ec5,
title = "The effects of strontium ranelate in Asian women with postmenopausal osteoporosis",
abstract = "The aim of this study was to assess the efficacy and safety of strontium ranelate in the treatment of postmenopausal women with osteoporosis in Taiwan. In this 12-month multicenter, randomized, double-blind, placebo-controlled study, 125 women with osteoporosis were randomly given either strontium ranelate 2 g daily or placebo. Lumbar spine, femoral neck, and total-hip bone mineral density (BMD) and biochemical markers of bone turnover were measured; adverse events and tolerability were recorded and assessed. Subjects treated with strontium ranelate showed significant increases in BMD of 5.9{\%} at the lumbar spine, 2.6{\%} at the femoral neck, and 2.7{\%} at the total hip, while the placebo group exhibited no significant change at 12 months. Serum level of a formation marker (bone-specific alkaline phosphatase) was also significantly increased at 6 and 12 months. Thus, although the sample size and the treatment duration of this study could not show its effect of reducing osteoprotic fractures, strontium ranelate showed bone protection effects by increasing BMD and concentrations of a bone formation marker. Safety assessment revealed adverse events were mild and not significantly different from placebo.",
author = "Hwang, {J. S.} and Chen, {J. F.} and Yang, {T. S.} and Wu, {D. J.} and Tsai, {K. S.} and C. Ho and Chih-Hsing Wu and Su, {S. L.} and Wang, {C. J.} and Tu, {S. T.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s00223-008-9180-z",
language = "English",
volume = "83",
pages = "308--314",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "5",

}

Hwang, JS, Chen, JF, Yang, TS, Wu, DJ, Tsai, KS, Ho, C, Wu, C-H, Su, SL, Wang, CJ & Tu, ST 2008, 'The effects of strontium ranelate in Asian women with postmenopausal osteoporosis', Calcified Tissue International, vol. 83, no. 5, pp. 308-314. https://doi.org/10.1007/s00223-008-9180-z

The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. / Hwang, J. S.; Chen, J. F.; Yang, T. S.; Wu, D. J.; Tsai, K. S.; Ho, C.; Wu, Chih-Hsing; Su, S. L.; Wang, C. J.; Tu, S. T.

In: Calcified Tissue International, Vol. 83, No. 5, 01.01.2008, p. 308-314.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of strontium ranelate in Asian women with postmenopausal osteoporosis

AU - Hwang, J. S.

AU - Chen, J. F.

AU - Yang, T. S.

AU - Wu, D. J.

AU - Tsai, K. S.

AU - Ho, C.

AU - Wu, Chih-Hsing

AU - Su, S. L.

AU - Wang, C. J.

AU - Tu, S. T.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The aim of this study was to assess the efficacy and safety of strontium ranelate in the treatment of postmenopausal women with osteoporosis in Taiwan. In this 12-month multicenter, randomized, double-blind, placebo-controlled study, 125 women with osteoporosis were randomly given either strontium ranelate 2 g daily or placebo. Lumbar spine, femoral neck, and total-hip bone mineral density (BMD) and biochemical markers of bone turnover were measured; adverse events and tolerability were recorded and assessed. Subjects treated with strontium ranelate showed significant increases in BMD of 5.9% at the lumbar spine, 2.6% at the femoral neck, and 2.7% at the total hip, while the placebo group exhibited no significant change at 12 months. Serum level of a formation marker (bone-specific alkaline phosphatase) was also significantly increased at 6 and 12 months. Thus, although the sample size and the treatment duration of this study could not show its effect of reducing osteoprotic fractures, strontium ranelate showed bone protection effects by increasing BMD and concentrations of a bone formation marker. Safety assessment revealed adverse events were mild and not significantly different from placebo.

AB - The aim of this study was to assess the efficacy and safety of strontium ranelate in the treatment of postmenopausal women with osteoporosis in Taiwan. In this 12-month multicenter, randomized, double-blind, placebo-controlled study, 125 women with osteoporosis were randomly given either strontium ranelate 2 g daily or placebo. Lumbar spine, femoral neck, and total-hip bone mineral density (BMD) and biochemical markers of bone turnover were measured; adverse events and tolerability were recorded and assessed. Subjects treated with strontium ranelate showed significant increases in BMD of 5.9% at the lumbar spine, 2.6% at the femoral neck, and 2.7% at the total hip, while the placebo group exhibited no significant change at 12 months. Serum level of a formation marker (bone-specific alkaline phosphatase) was also significantly increased at 6 and 12 months. Thus, although the sample size and the treatment duration of this study could not show its effect of reducing osteoprotic fractures, strontium ranelate showed bone protection effects by increasing BMD and concentrations of a bone formation marker. Safety assessment revealed adverse events were mild and not significantly different from placebo.

UR - http://www.scopus.com/inward/record.url?scp=58549102898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549102898&partnerID=8YFLogxK

U2 - 10.1007/s00223-008-9180-z

DO - 10.1007/s00223-008-9180-z

M3 - Article

C2 - 18843436

AN - SCOPUS:58549102898

VL - 83

SP - 308

EP - 314

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 5

ER -